• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    102.01 +0.02 (+0.02%)
    Streaming Delayed Price Updated: 9:44 AM EST, Jan 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Incyte Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
    From Incyte
    Via Business Wire
    News headline image
    Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Incyte
    Via Business Wire
    News headline image
    Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces Change to its Board of Directors
    From Incyte
    Via Business Wire
    News headline image
    Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
    From Incyte
    Via Business Wire
    News headline image
    Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte Corporation
    Via Business Wire
    News headline image
    Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
    From Incyte
    Via Business Wire
    News headline image
    Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
    From Incyte
    Via Business Wire
    News headline image
    Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Incyte
    Via Business Wire
    News headline image
    Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
    From Incyte and Enable Injections
    Via Business Wire
    News headline image
    Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
    From Incyte
    Via Business Wire
    News headline image
    Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Report Third Quarter Financial Results
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
    From Incyte
    Via Business Wire
    News headline image
    Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.